PN Is Moving Beyond “Skin Booster” Territory
For a while, polynucleotides have mostly occupied a familiar corner of aesthetic medicine: skin quality, hydration, elasticity and the rather vague promise of “regeneration.”
But the research is beginning to move into a different territory.
Instead of asking whether PN can make skin look better, researchers and clinicians are starting to investigate what happens when it is used on skin that is damaged, healing or behaving abnormally.
That includes wounds, scars, postoperative recovery and compromised tissue.
When skin actually needs to repair
A 2026 case series described injectable PN being used after aesthetic procedures in eight patients with problems including delayed wound healing, early ischemic changes, wound separation, hypertrophic scarring and postoperative contour depression.
The treatment used Rejuran, with the injection approach adapted to the condition being treated. All eight patients showed clinical improvement, including wound closure, re-epithelialisation, reduced erythema, scar flattening or improvement in postoperative contour.
Sequential clinical photographs from a 2026 case series examining injectable PN in postoperative wound repair and scar modulation (Park et al., 2026).
The photographs are striking.
But photographs of eight patients are not the same thing as a clinical trial.
The study was retrospective, the cases were heterogeneous, and outcomes were assessed primarily through clinical photographs and physician observation. The authors describe the findings as encouraging, but also call for larger prospective studies and standardised outcome measures.
So this is a signal, not proof.
Then there is the real-world evidence
The story doesn't stop with one small case series.
A May 2026 real-world study looked at how injectable polynucleotides were being used in clinical practice for scar management. The reported applications extended beyond cosmetic skin quality into tissue response, scar appearance and wound recovery.
That kind of evidence is different from a controlled clinical trial. It tells us more about what clinicians are actually doing in practice, rather than proving that PN is responsible for a particular outcome.
But it does show that the clinical conversation is expanding.
PN is no longer appearing only in the language of skin boosters.
And the broader evidence is starting to catch up
A 2026 systematic review of randomized clinical trials looked specifically at PN and PDRN across skin rejuvenation, postoperative scar prevention and wound healing.
Across the included studies, the researchers found evidence of improvements in several outcomes, including wrinkle-related measures, scar quality and wound-healing measures. The review also found that the evidence was strongest in some areas than others, and that differences between formulations, protocols and outcome measures make the literature difficult to interpret as one single body of evidence.
That distinction matters.
A growing number of positive studies doesn't automatically mean we now have a clear answer about what PN does.
It means we have more questions we can start asking properly.
Read the 2026 systematic review
PN and PDRN aren't quite the same story
Part of the confusion comes from the fact that PN and PDRN are often discussed together, and sometimes almost interchangeably.
They are related DNA-derived materials, but their proposed mechanisms are not identical.
PDRN has traditionally been discussed in terms of biological signalling, including pathways associated with inflammation, angiogenesis and tissue repair. PN is increasingly described in terms of its larger molecular structure and its potential to provide a three-dimensional scaffold within tissue.
That distinction is still being debated and standardised, but it changes the way we might think about the materials.
One is not simply a more expensive version of the other.
From skin quality to tissue repair
For aesthetic medicine, this creates an interesting shift.
The familiar conversation has been:
hydration → elasticity → texture → skin quality
The newer questions are moving towards:
wound healing → compromised tissue → scar modulation → tissue restoration
Those are not necessarily the same biological problem.
A treatment designed to improve the appearance and quality of otherwise healthy skin is one thing. Using a material in tissue that has been injured, is healing poorly or is developing an abnormal scar raises a different set of questions.
What is happening to the extracellular environment?
How are cells responding?
Is the material changing signalling, providing structural support, or both?
And how much of the observed improvement is actually caused by the PN itself?
This is where the evidence gets important
It would be very easy to look at the photographs from the case series and conclude that PN heals wounds or prevents scars.
The evidence doesn't allow us to go that far yet.
The eight-patient study has no control group. The real-world data reflect clinical practice rather than randomised comparison. And even the newer systematic review points to variation between studies, products, treatment protocols and outcome measures.
So the question isn't whether PN has suddenly been proven to be a wound-healing treatment.
It hasn't.
What has changed is that there is now enough clinical and research activity to make the question worth taking seriously.
What are we actually asking the tissue to do?
This is the part I find more interesting than the phrase “skin booster.”
Aesthetic medicine has traditionally been very good at describing what we can add to the face: filler, volume, hydration, collagen stimulation.
The newer language is different.
It is increasingly about what we can persuade the tissue to do.
Repair.
Remodel.
Reorganise.
Perhaps that is where PN becomes more interesting as a research subject — not because it has been proven to regenerate everything it touches, but because it sits at the intersection of material science, cell signalling and tissue repair.
The evidence is still developing.
But the question has changed.
C·🌷
Research notes
PN therapy for wound repair and scar modulation
Park et al., 2026
Polynucleotide (PN) Therapy for Accelerated Wound Repair and Scar Modulation in Aesthetic Procedures.
Retrospective case series of eight patients treated with injectable PN following aesthetic procedures or facial trauma.
Real-world use of PN in scar management
2026
Real-World Use of Polynucleotide Injections in Scar Management: A Multicenter Clinical Study.
Real-world clinical data examining how injectable PN is being used in scar management and tissue recovery.
PN and PDRN across clinical applications
Alhussain et al., 2026
Polynucleotides and Polydeoxyribonucleotides for Skin Rejuvenation, Postoperative Scar Prevention, and Wound Healing: A Systematic Review of Randomized Clinical Trials.
Systematic review examining randomized clinical evidence across skin rejuvenation, postoperative scar prevention and wound healing.